Immunogenic Hepatitis E Virus Polypeptides for Vaccine and Diagnostics Development


This technology comprises specific hepatitis E virus (HEV) antigenic polypeptides. HEV causes epidemic and sporadic cases of hepatitis outbreaks with a mortality rate as high as 20% for pregnant women. In order to address this problem, CDC scientists carried out thorough HEV antigen screenings and subsequently developed recombinant proteins that efficiently model major HEV neutralization epitope(s). These recombinant proteins may be considered as candidates for the development of an HEV subunit vaccine, as well as for the development of highly sensitive and specific diagnostic tests.

Potential Commercial Applications: Competitive Advantages:
  • Development of a peptide subunit-based vaccine for hepatitis E virus (HEV)
  • Development of HEV sero-diagnostic tools and reagents
  • Blood transfusion screening
  • Pregnancy screening safety precautions
  • Hepatitis monitoring programs
  • Basic research into hepatitis pathogenicity and immune response
 
  • Generated antibodies were cross-reactive with a number of geographically distinct HEV strains
  • Useful for development of highly sensitive and specific diagnostic tests
  • Could be useful for improving efficacy and HEV-strain immunity provided by current vaccine(s)


Development Stage:
In vitro data available

Inventors:

Howard Fields (CDC)  ➽ more inventions...

Yury Khudyakov (CDC)  ➽ more inventions...

Jihong Meng (CDC)  ➽ more inventions...


Intellectual Property:
US Application No. 10/257,044
PCT Application No. PCT/US2001/010696
US Application No. 60/195,380
Various international patents issued

Publications:
Meng J, et al. PMID 11601892

Licensing Contact:
Karen Surabian, J.D., M.B.A.
Email: karen.surabian@nih.gov
Phone: 301-594-9719

OTT Reference No: E-152-2013/0
Updated: Jan 20, 2014